Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5415]

Comment: Adjuvant ipilimumab in high-risk melanoma

Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA

Comment: Adjuvant ipilimumab in high-risk melanoma ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )

Comment: PD-1 targeting MK-3475 gives long-term responses in melanoma

Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA

Comment: PD-1 targeting MK-3475 gives long-term responses in melanoma ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )

Comment: Immunotherapy combo increases median survival in advanced melanoma

Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA

Comment: Immunotherapy combo increases median survival in advanced melanoma ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )

Success for ipilimumab and nivolumab combo in advanced melanoma

Prof Mario Sznol - Yale Cancer Center, New Haven, USA

Success for ipilimumab and nivolumab combo in advanced melanoma ( Prof Mario Sznol - Yale Cancer Center, New Haven, USA )

Comment: CALGB/SWOG 80405 study on chemo combos in colorectal

Prof Marc Peeters - University of Antwerp, Antwerp, Belgium

Comment: CALGB/SWOG 80405 study on chemo combos in colorectal ( Prof Marc Peeters - University of Antwerp, Antwerp, Belgium )

Discontinuing statins near the end of life is safe, improves patient quality of...

Prof Amy P. Abernethy - Duke University School of Medicine, Durham, USA

Discontinuing statins near the end of life is safe, improves patient quality of life ( Prof Amy P. Abernethy - Duke University School of Medicine, Durham, USA )

Phase III SELECT trial shows lenvatinib to be effective in resistant thyroid...

Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France

Phase III SELECT trial shows lenvatinib to be effective in resistant thyroid cancer ( Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France )

Inhibition of PD-L1 using drug MPDL3280A for patients with metastatic...

Prof Thomas Powles - Barts Health, London, UK

Inhibition of PD-L1 using drug MPDL3280A for patients with metastatic urothelial bladder cancer ( Prof Thomas Powles - Barts Health, London, UK )

Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute...

Prof Max Topp - Würzburg University Hospital, Würzburg, Germany

$Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute lymphoblastic leukaemia ( Prof Max Topp - Würzburg University Hospital, Würzburg, Germany )$

Regorafenib shows early promise in colorectal candidates unable to undergo chemo

Dr Enrique Grande - Hospital Ramon y Cajal, Madrid, Spain

Regorafenib shows early promise in colorectal candidates unable to undergo chemo ( Dr Enrique Grande - Hospital Ramon y Cajal, Madrid, Spain )

Lower-dose radiation safe for certain lower-risk, HPV-positive head and neck...

Prof Anthony Cmelak - Vanderbilt-Ingram Cancer Center, Nashville, USA

Lower-dose radiation safe for certain lower-risk, HPV-positive head and neck cancers ( Prof Anthony Cmelak - Vanderbilt-Ingram Cancer Center, Nashville, USA )

ASCO 2014 roundup

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

ASCO 2014 roundup ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

More from ecancer